How big is Zynex, Inc.?

As of Jun 18, Zynex, Inc. has a market capitalization of 74.31 million and reported net sales of 172.40 million with a net profit of -7.41 million over the latest four quarters. Shareholder's funds are 35.71 million, and total assets amount to 126.11 million.

As of Jun 18, Zynex, Inc. has a market capitalization of 74.31 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 172.40 million, while the sum of net profit for the same period is -7.41 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 35.71 million, and total assets amount to 126.11 million.

What does Zynex, Inc. do?

Zynex, Inc. manufactures medical devices for treating pain and rehabilitating muscles, with a market cap of $74.31 million and quarterly net sales of $27 million but a net loss of $10 million as of March 2025. Key metrics include a debt-to-equity ratio of 1.89 and a return on equity of -35.68%.

Overview: <BR>Zynex, Inc. manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot: <BR>Net Sales: 27 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 74.31 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 1.89 <BR>Return on Equity: -35.68% <BR>Price to Book: 3.58<BR><BR>Contact Details: <BR>Address: 9555 MAROON CIRCLE, ENGLEWOOD CO: 80112 <BR>Tel: ['1 303 8673904', '1 800 4956670'] <BR>Fax: 1 800 4956695 <BR>Website: https://www.zynex.com/

Should I buy, sell or hold Zynex, Inc.?

Who are in the management team of Zynex, Inc.?

As of March 2022, Zynex, Inc.'s management team includes Mr. Thomas Sandgaard as Chairman, President, and CEO, along with independent directors Mr. Michael Cress, Mr. Joshua Disbrow, and Mr. Barry Michaels.

As of March 2022, the management team of Zynex, Inc. includes Mr. Thomas Sandgaard, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features independent directors: Mr. Michael Cress, Mr. Joshua Disbrow, and Mr. Barry Michaels.

Is Zynex, Inc. overvalued or undervalued?

As of April 29, 2025, Zynex, Inc. is considered risky and overvalued due to negative financial metrics and a year-to-date return of -80.65%, significantly underperforming the S&P 500's 12.22%.

As of 29 April 2025, the valuation grade for Zynex, Inc. has moved from expensive to risky, indicating a deterioration in its perceived value. The company appears to be overvalued given its negative financial metrics, with a Price to Book Value of 3.30, an EV to EBIT of -14.15, and an EV to Sales ratio of 0.63. In comparison, peers such as CareDx, Inc. have a very attractive valuation with a P/E of -27.9089, while Organogenesis Holdings, Inc. is also risky with a P/E of 608.5864, highlighting Zynex's struggles within its industry.<BR><BR>The stock has significantly underperformed against the S&P 500, with a year-to-date return of -80.65% compared to the index's 12.22%. This stark contrast reinforces the notion that Zynex is currently overvalued, as its financial performance does not support its market price.

Is Zynex, Inc. technically bullish or bearish?

As of August 1, 2025, Zynex, Inc. is in a bearish trend with weak strength indicators, significantly underperforming the S&P 500 with year-to-date and one-year returns of -80.65% and -81.05%, respectively.

As of 1 August 2025, the technical trend for Zynex, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the weekly KST being bearish. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly, which adds to the mixed signals. The Bollinger Bands and OBV are also indicating bearish trends. <BR><BR>In terms of performance, Zynex has significantly underperformed compared to the S&P 500, with a year-to-date return of -80.65% versus the S&P 500's 12.22%, and a one-year return of -81.05% compared to 17.14% for the index.